KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Other financing activities (2016 - 2025)

Astrana Health's Other financing activities history spans 13 years, with the latest figure at $4.0 million for Q3 2025.

  • For Q3 2025, Other financing activities rose 618.76% year-over-year to $4.0 million; the TTM value through Sep 2025 reached $59.1 million, up 377.74%, while the annual FY2024 figure was $34.8 million, N/A changed from the prior year.
  • Other financing activities for Q3 2025 was $4.0 million at Astrana Health, down from $11.8 million in the prior quarter.
  • Across five years, Other financing activities topped out at $35.4 million in Q4 2024 and bottomed at -$773000.0 in Q3 2024.
  • The 5-year median for Other financing activities is $5.0 million (2023), against an average of $7.2 million.
  • The largest annual shift saw Other financing activities skyrocketed 19575.86% in 2023 before it crashed 113.55% in 2024.
  • A 5-year view of Other financing activities shows it stood at -$679000.0 in 2021, then surged by 2461.41% to $16.0 million in 2022, then crashed by 64.41% to $5.7 million in 2023, then skyrocketed by 520.93% to $35.4 million in 2024, then tumbled by 88.68% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Other financing activities are $4.0 million (Q3 2025), $11.8 million (Q2 2025), and $7.9 million (Q1 2025).